Table 1 Demographic and baseline characteristics
|  | Total n = 190 | Saxagliptin n = 66 | Vildagliptin n = 63 | Sitagliptin n = 61 | p value |
|---|---|---|---|---|---|
Age (years), mean ± SD | 46.6 ± 9.0 | 46.5 ± 10.7 | 44.8 ± 8.5 | 48.6 ± 11.3 | 0.90 |
Range | 23 ~ 72 | 23 ~ 72 | 25 ~ 63 | 29 ~ 70 | - |
Age (years), n (%) | |||||
<50Â years | 53(28%) | 18(27%) | 18(29%) | 17(27%) | 0.99 |
50 ~ 65 years | 90(47%) | 31(47%) | 29(46%) | 30(50%) | 0.94 |
>65Â years | 47(25%) | 17(26%) | 16(25%) | 14(23%) | 0.93 |
Gender, n (%) | |||||
Male | 109(57%) | 39(59%) | 37(59%) | 33(54%) | 0.82 |
Female | 81(43%) | 27(41%) | 26(41%) | 28(46%) | 0.82 |
Duration of diabetes (years), n (%) | |||||
<1Â year | 61(32%) | 20(30%) | 24(38%) | 17(28%) | 0.44 |
1 ~ 5 years | 69(36%) | 24(37%) | 21(33%) | 24(40%) | 0.79 |
>5Â years | 60(32%) | 22(33%) | 18(29%) | 20(32%) | 0.82 |
Body weight (kg), mean ± SD | 74.4 ± 11.1 | 77.2 ± 15.1 | 72.7 ± 11.3 | 73.2 ± 10.9 | 0.89 |
BMI (kg/m2), mean ± SD | 26.3 ± 2.8 | 26.9 ± 3.1 | 25.3 ± 2.8 | 26.6 ± 3.3 | 0.80 |
HbA1c (%), mean ± SD | 8.72 ± 1.01 | 8.86 ± 1.13 | 8.75 ± 1.15 | 8.54 ± 1.19 | 0.94 |
FBG (mmol/l), mean ± SD | 8.46 ± 1.61 | 8.36 ± 2.04 | 8.79 ± 1.80 | 8.22 ± 1.77 | 0.93 |
P2hBG(mmol/l), mean ± SD | 11.58 ± 2.49 | 11.77 ± 3.07 | 11.98 ± 2.46 | 10.98 ± 2.93 | 0.90 |
Therapy, n (%) | |||||
Metformin with glimepiride | 77(41%) | 26(40%) | 26(41%) | 25(41%) | 0.97 |
Metformin with acarbose | 62(33%) | 22(33%) | 20(32%) | 20(33%) | 0.98 |
Metformin with pioglitazone | 51(26%) | 18(27%) | 17(27%) | 16(26%) | 0.99 |